Following a successful Type C meeting with the FDA, Xinnate's upcoming STEP trial for TCP-25 in Epidermolysis Bullosa patients has been upgraded to serve as a registrational trial.
The US FDA has granted Orphan Drug Designation to Xinnate's TCP-25, an immunomodulatory peptide developed for treating the rare skin disease Epidermolysis Bullosa.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.